Cover capital-return programs, executive changes and pay, the stock screener, federal contract awards, and scheduled FDA advisory-committee catalysts. Figures come from SEC filings, USAspending, and the FDA's own calendar; nothing is estimated.
GetBuybackPrograms
A company's share-repurchase picture — tracked programs (authorized total, remaining, expiry), the latest authorization, and the repurchase history (cash spent, shares, average price) by fiscal year — from XBRL facts plus verified extractions of the filings' narrative. Nothing is estimated.
Parameters: ticker (required).
Ask: "How much stock has NVIDIA been buying back?"
Returns (trimmed):
# Share repurchases — NVDA (Nvidia Corp)
## Tracked programs
| Announced | Authorized | Remaining | As of | Source |
|------------|----------------:|----------------:|------------|------------------|
| 2026-05-18 | $80,000,000,000 | $38,500,000,000 | 2026-04-26 | 8-K, 2026-05-20 |
## Repurchase history (fiscal years)
| Fiscal year ended | Cash spent | Shares | Source |
|-------------------|----------------:|------------:|-------------------|
| 2026-01-25 | $40,086,000,000 | 282,000,000 | 10-K, 2026-02-25 |
GetAtmPrograms
At-the-market (ATM) equity programs — the standing arrangements under which a company sells new shares directly into the market. Returns each program's size, amount sold, and remaining capacity from the filing that established it. Coverage is rolling out across issuers; a company with no imported program returns a clear notice rather than a guess.
Parameters: ticker (required).
Ask: "Does NVIDIA have an at-the-market equity program?"
Returns:
No at-the-market offering program has been imported for NVDA yet.
GetExecutiveChanges
Executive and director appointments and departures, extracted from Item-5.02 8-K filings — each with the person, role, the nature of the change, its effective date, and the verbatim disclosure. Names and roles are exactly as the company filed them.
Parameters: ticker (required), maxResults.
Ask: "Any recent executive changes at NVIDIA?"
Returns (trimmed):
# Executive changes — NVDA (Nvidia Corp)
| Filed | Person | Role | Change | Effective |
|------------|-----------------|--------------------------------------------------|-----------|------------|
| 2026-07-02 | Nicholas Parker | Executive Vice President, Worldwide Field Ops | Appointed | 2026-08-24 |
GetExecutiveCompensation
Named-executive pay from the company's DEF 14A Summary Compensation Table — salary, bonus, stock and option awards, non-equity incentive, other, and the company-reported total, per fiscal year. Amounts are nominal USD exactly as disclosed.
Parameters: ticker (required).
Ask: "What does NVIDIA pay its top executives?"
Returns (trimmed to fiscal 2022):
# Executive compensation — NVDA (Nvidia Corp)
## Fiscal 2022
| Executive | Role | Salary | Stock awards | Non-equity incentive | Total |
|-----------------|---------------|---------:|-------------:|---------------------:|------------:|
| Jen-Hsun Huang | CEO | $996,216 | $18,660,407 | $4,000,000 | $23,737,661 |
| Colette Kress | CFO | $896,595 | $8,269,020 | $600,000 | $9,775,927 |
ScreenStocks
Screen the whole US universe by combining range filters across datasets — market cap, price, 13F filer count and its quarter-over-quarter change, short interest %, days to cover, the composite squeeze and insider-sentiment scores, net insider buying, and the going-concern flag. Every bound is optional.
Key parameters: minMarketCap / maxMarketCap, minSqueezeScore, minShortInterestPercent, minInsiderSentiment, minNetInsiderBuy, hasGoingConcernDoubt, sortBy, maxResults (every axis has a min/max).
Ask: "Screen for $1B+ stocks with a squeeze score above 75."
Returns (trimmed):
# Stock screener — 307 match(es), showing 3
| Ticker | Company | Market Cap | SI % | Days to Cover | Squeeze | Net Insider Buy (90d) |
|--------|------------------|-----------:|-------:|--------------:|--------:|----------------------:|
| SNOW | Snowflake Inc. | $93.1B | 6.65% | 2.94 | 76 | -$470.3M |
| TRV | Travelers Cos. | $72.6B | 3.74% | 2.86 | 75 | -$12.8M |
| NBIS | Nebius Group N.V.| $55.8B | 27.68% | 3.46 | 85 | -$141.1M |
GetGovernmentContracts
Federal contract awards won by a company, from USAspending — each with the action date, awarding agency, award type, dollar amount, award ID, and description, newest first.
Parameters: ticker (required), startDate, endDate, maxResults.
Ask: "What federal contracts has Lockheed Martin won recently?"
Returns (trimmed):
Federal contract awards for LMT (Lockheed Martin Corp):
| Action Date | Agency | Type | Amount | Description |
|-------------|-----------------------|----------------|-------------:|--------------------------------------|
| 2026-06-01 | Department of Defense | Delivery Order | $118,248,309 | C-130J/DMS A2 GROUPING |
| 2025-10-31 | Department of Defense | Delivery Order | $70,586,574 | C-130J FY22 STAR XIII MISSION UPGRADE|
GetTopGovernmentContractors
The companies that have won the most federal contract dollars over a window, ranked by total awarded, with the award count. Useful for sizing defense- and services-exposure across names.
Parameters: startDate, endDate, maxResults.
Ask: "Which public companies won the most federal contracts this year?"
Returns:
Top federal contractors (2025-07-14 to 2026-07-14):
| Rank | Ticker | Company | Total Awarded | Awards |
|------|--------|----------------------|--------------:|-------:|
| 1 | LMT | Lockheed Martin Corp | $188,834,883 | 2 |
GetFdaCatalysts
Scheduled FDA advisory-committee meetings — the events that can move biotech and pharma names — soonest first, with the date, meeting title, FDA center, and type. Straight from the FDA's own calendar.
Parameters: startDate, endDate, maxResults.
Ask: "What FDA advisory meetings are coming up?"
Returns (trimmed):
FDA Catalyst Calendar (advisory-committee meetings):
| Date | Meeting | Center | Type |
|------------|----------------------------------------------------|--------|--------------------------|
| 2026-07-23 | Pharmacy Compounding Advisory Committee | CDER | Advisory Committee Meeting |
| 2026-07-29 | Cellular, Tissue, and Gene Therapies Adv. Committee| CBER | Advisory Committee Meeting |